Johnson & Johnson (NYSE:JNJ) Given New $232.00 Price Target at Leerink Partners

Johnson & Johnson (NYSE:JNJ) had its price target lifted by Leerink Partners from $201.00 to $232.00 in a research report report published on Thursday,MarketScreener reports. The firm currently has a market perform rating on the stock.

JNJ has been the subject of a number of other reports. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, January 17th. Freedom Capital cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Barclays increased their price target on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Finally, Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $224.82.

Johnson & Johnson Trading Up 0.4%

NYSE:JNJ traded up $0.80 during trading hours on Thursday, hitting $219.29. 674,627 shares of the stock were exchanged, compared to its average volume of 9,340,856. The company has a market capitalization of $528.33 billion, a P/E ratio of 19.86, a price-to-earnings-growth ratio of 2.24 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $207.86 and its two-hundred day moving average is $188.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $222.17.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. The business had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vista Investment Partners II LLC lifted its position in shares of Johnson & Johnson by 1.2% in the fourth quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company’s stock valued at $789,000 after buying an additional 47 shares during the last quarter. Campbell Deegan Wealth Management LLC raised its stake in Johnson & Johnson by 1.6% in the 4th quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company’s stock valued at $619,000 after acquiring an additional 48 shares during the period. Centennial Wealth Advisory LLC lifted its holdings in Johnson & Johnson by 2.2% during the 4th quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company’s stock valued at $473,000 after purchasing an additional 49 shares during the last quarter. Gleason Group Inc. boosted its position in Johnson & Johnson by 0.8% during the fourth quarter. Gleason Group Inc. now owns 6,390 shares of the company’s stock worth $1,322,000 after purchasing an additional 50 shares during the period. Finally, ACT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 3.9% in the fourth quarter. ACT Wealth Management LLC now owns 1,399 shares of the company’s stock valued at $290,000 after purchasing an additional 52 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat and raised 2026 outlook — JNJ topped earnings and revenue estimates, reported stronger organic growth and issued 2026 guidance that management says should exceed Street expectations, supporting bullish sentiment. JNJ Tops Q4 Earnings
• Positive Sentiment: Analyst upgrades and higher targets — Several firms raised price targets (notably Scotiabank to $265) and the consensus broker view is skewed toward buy/moderate buy, which supports further upside. Scotiabank Raises JNJ Target
• Positive Sentiment: Dividend credibility and cash returns — J&J’s Dividend King status (63+ years of raises), healthy payout ratio and buyback capacity keep income investors supportive. Dividend King Analysis
• Neutral Sentiment: Technical setup — Analysts/market outlets note a trend?following buy signal after the post?earnings pullback, which can attract momentum flows but is dependent on macro/sector breadth. MarketBeat Technical Note
• Neutral Sentiment: Media and TV endorsements — Positive commentary from high?profile commentators (e.g., Jim Cramer) may underpin short?term interest but has limited fundamental impact. Jim Cramer on JNJ
• Negative Sentiment: Talc litigation advances — A court decision cleared the way for plaintiffs’ expert testimony in the talc MDL, a legal overhang that can resume volatility and possible liability risk. Talc Litigation Update
• Negative Sentiment: Stelara biosimilar pressure — Loss of Stelara patent protection and accelerating biosimilar competition dented prior sales and remain a medium?term headwind for revenue mix. Stelara Biosimilar Headwind
• Negative Sentiment: Drug?pricing deal cost — Management flagged “hundreds of millions” of costs tied to a recent drug?pricing agreement, which modestly offsets EPS upside in 2026. Guidance & Pricing Headwind

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.